NovaBridge Biosciences (NBP) General Counsel submits initial Form 3

Rhea-AI Filing Summary

NovaBridge Biosciences General Counsel Lin Liwei Lorraine has filed an initial statement of beneficial ownership on Form 3 as an officer of the company. The filing identifies her role as General Counsel but does not list any stock purchases, sales, or other transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lin Liwei Lorraine

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the NovaBridge Biosciences (NBP) Form 3 filing show?

The Form 3 filing shows that Lin Liwei Lorraine is an officer of NovaBridge Biosciences serving as General Counsel. It is an initial statement of beneficial ownership and does not report any stock transactions or changes in holdings.

Who is the reporting person in NovaBridge Biosciences (NBP) Form 3?

The reporting person is Lin Liwei Lorraine, who is identified as an officer of NovaBridge Biosciences. Her specific title is General Counsel, meaning she is the company’s top legal executive and subject to insider reporting obligations.

Does the NovaBridge Biosciences (NBP) Form 3 report any stock purchases or sales?

The Form 3 does not report any stock purchases, sales, or other equity transactions by Lin Liwei Lorraine. It functions solely as an initial disclosure of her insider status as General Counsel, with no transactional activity listed in the filing.

What is the role of Lin Liwei Lorraine at NovaBridge Biosciences (NBP)?

Lin Liwei Lorraine is listed as an officer of NovaBridge Biosciences with the title General Counsel. This role typically includes overseeing legal matters and compliance, which also makes her subject to insider reporting rules such as Form 3 filings.

Why is NovaBridge Biosciences (NBP) General Counsel filing a Form 3?

Form 3 is required when someone becomes an officer, director, or significant shareholder of a public company. As General Counsel of NovaBridge Biosciences, Lin Liwei Lorraine must file Form 3 to disclose her status as an insider and any initial ownership position.